AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A Peptide comprising the sequence of amino acids selected from:

- the sequence 13-39 of the HARP factor ; and
- the sequence 65-97 of the HARP factor.

2. (currently amended) A Peptide comprising a sequence of amino acids at least 80 % similar to the sequence SEQ ID N° 2 or N° 3, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to glycoaminoglycans (GAG).

3. (currently amended) The Peptide according to Claim 2, in which the sequence differs from the sequence SEQ ID N° 2 or N° 3 by the conservative substitution of at least one amino acid.

4. (currently amended) A Nucleic acid comprising a sequence coding for a peptide ~~as defined in any one of Claims 1 to 3~~ according to claim 1.

5. (currently amended) The Nucleic acid according to Claim 4, comprising the sequence SEQ ID N° 5 or SEQ ID N° 6.

6. (currently amended) A Method of production of a peptide ~~as defined in any one of Claims 1 to 3~~ according to claim 1, comprising the synthesis of the said peptide by chemical means.

7. (currently amended) A Method of production of a peptide ~~as defined in any one of Claims 1 to 3~~ according to claim 1, in which a vector containing a nucleic acid ~~as defined in Claim 4 or 5~~ that encodes said peptide is transferred into a host cell

which is cultured under conditions permitting the expression of the corresponding peptide.

8. (currently amended) A Pharmaceutical composition comprising a peptide ~~as defined in any one of Claims1 to 3~~ according to claim 1, and one or more pharmaceutically acceptable excipients.

9. (currently amended) The Composition according to Claim 8, further comprising a peptide having the sequence of amino acids 111-136 of the HARP factor or a peptide comprising a sequence of amino acids at least 80 % similar to the sequence SEQ ID N° 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

10. (currently amended) The Composition according to Claim 9, comprising :

- the peptide 13-39 of sequence SEQ ID N° 2 ;
- the peptide 65-97 of sequence SEQ ID N° 3 ; et
- the peptide 111-136 of sequence SEQ ID N° 4.

11. (currently amended) A Pharmaceutical composition comprising a nucleic acid comprising a sequence ~~coding~~ encoding for a peptide as ~~defined in any one of Claims 1 to 3~~ according to claim 1.

12. (currently amended) The Composition according to Claim 11, further comprising a nucleic acid comprising a sequence ~~coding~~ encoding for a peptide ~~as defined in Claim 9~~ having the sequence of amino acids 111-136 of the HARP factor or a peptide comprising a sequence of amino acids at least 80% similar to the sequence of SEQ ID N°4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

13. (currently amended) The Composition according to Claim 12, comprising :

- a nucleic acid coding for the peptide 13-39 of sequence SEQ ID N° 2 ;
- a nucleic acid coding for the peptide 65-97 of sequence SEQ ID N° 3 ;
- a nucleic acid coding for the peptide 111-136 of sequence SEQ ID N° 4.

14. (currently amended) The Composition according to Claim 12 [[or 13]], in which the said nucleic acids are carried by one single vector.

15. (currently amended) ~~Use of a peptide as defined in any one of Claims 1 to 3~~ A method for the preparation of a medicament ~~intended~~ for the treatment of a pathology associated with an angiogenesis , comprising adding the peptide according to claim 1 to a pharmaceutically acceptable vehicle.

16. (currently amended) ~~Use according to Claim 15, in which the peptide as defined in any one of Claims 1 to 3 is~~ The method according to claim 15, wherein said peptide associated with a second peptide having the sequence of amino acids 111-136 of the HARP factor or with a peptide comprising a sequence of amino acids at least 80 % similar to the sequence SEQ ID N° 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

17. (currently amended) ~~Use of a nucleic acid as defined in either Claim 4 or Claim 5~~ A method for the preparation of a medicament intended for the treatment of a pathology associated with an angiogenesis , comprising adding a nucleic acid according to claim 4 to said medicament.

18. (currently amended) ~~Use~~ The method according to Claim 17, in which the nucleic acid ~~as defined in either Claim 4 or Claim 5~~ is

associated with a nucleic acid comprising a sequence ~~coding~~ encoding for a ~~peptide as defined in Claim 9~~ peptide having the sequence of amino acids 111-136 of the HARP factor or a peptide comprising a sequence of amino acids at least 80% similar to the sequence of SEQ ID N°4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

19. (currently amended) ~~Use~~ The method according to ~~any one of Claims 15 to 18~~ claim 15, in which the pathology is a tumour, an ocular lesion, rheumatoid polyarthritis or a skin disease.